Fig. 4

Receiver operating characteristic curves for CA125 and CEA in CA19-9-negative patients. Receiver operating characteristic curves of CA125 (A) and CEA (B) for predicting malignant IPMNs in CA19-9-negative patients. AUC, area under curve; CA19-9, carbohydrate antigen 19-9; CA125, carbohydrate antigen 125; CEA, carcinoembryonic antigen; IPMN, intraductal papillary mucinous neoplasm; ROC, receiver operating characteristic curves